Zhang Zhigong, Lin Feng, He Zhipeng, Wang Haoran, Zhu Xingyang, Cheng Tingting
Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Anhui Public Health Clinical Center, Hefei, China.
Front Surg. 2023 Jan 5;9:1071600. doi: 10.3389/fsurg.2022.1071600. eCollection 2022.
To compare the clinical characteristics of Stanford type B aortic intramural hematoma (IMH) and Stanford type B aortic dissection (AD), and to identify the differences between thoracic endovascular aortic repair (TEVAR) and medical management (MM) in the Stanford type B IMH patients.
A retrospective observational study was conducted in patients treated between January 2015 and December 2016. The clinical characteristics and CT images of patients with type B IMH and type B AD were compared, and the clinical characteristics and CT images of patients in the type B IMH group who were treated with TEVAR and MM were compared.
A total of 176 patients were included in this study, including 62 patients of type B IMH and 114 patients of type B AD. Five patients died in the IMH group and three in the AD group. The proximal hematoma or entry tear in both groups was mainly located in the descending aorta, and the proportion of the iliac artery involved in the AD group was significantly higher than that in the IMH group (31.6% vs. 8.1% < 0.05). There were 50 MM patients and 12 TEVAR patients in the IMH group. No death occurred in the TEVAR group, while five patients in the MM group died. Seven patients in the MM group had disease progression vs. 12 in the TEVAR group ( < 0.05). The patients in the TEVAR group had more intima lesions than those in the MM group (83.3% vs. 30.0%, < 0.05). TEVAR group involved more iliac artery hematoma than MM group (33.3% vs. 2.0%, < 0.05). The maximum thickness of hematoma in TEVAR group was 14.9 ± 3.4 mm, which was significantly larger than that of MM group (10.2 ± 2.8 mm) ( < 0.05).
In the diagnosis of IMH, patients' symptoms and high-risk signs of CTA should be paid attention to. TEVAR therapy should be actively considered on the basis of effective medical management when there are intima lesions (ULP/PAU), increased aortic diameter and hematoma thickness, extensive hematoma involvement, and pleural effusion.
比较B型主动脉壁内血肿(IMH)和B型主动脉夹层(AD)的临床特征,明确B型IMH患者腔内修复术(TEVAR)与药物治疗(MM)的差异。
对2015年1月至2016年12月间接受治疗的患者进行回顾性观察研究。比较B型IMH和B型AD患者的临床特征及CT影像,并比较B型IMH组中接受TEVAR和MM治疗患者的临床特征及CT影像。
本研究共纳入176例患者,其中B型IMH患者62例,B型AD患者114例。IMH组5例死亡,AD组3例死亡。两组近端血肿或破口主要位于降主动脉,AD组髂动脉受累比例显著高于IMH组(31.6%比8.1%,<0.05)。IMH组中,MM治疗患者50例,TEVAR治疗患者12例。TEVAR组无死亡病例,MM组5例死亡。MM组7例病情进展,TEVAR组12例(<0.05)。TEVAR组内膜病变患者多于MM组(83.3%比30.0%,<0.05)。TEVAR组髂动脉血肿累及情况多于MM组(33.3%比2.0%,<0.05)。TEVAR组血肿最大厚度为14.9±3.4 mm,显著大于MM组(10.2±2.8 mm)(<0.05)。
IMH诊断中应关注患者症状及CTA高危征象。存在内膜病变(ULP/PAU)、主动脉直径增大、血肿厚度增加、血肿广泛累及及胸腔积液时,在有效药物治疗基础上应积极考虑TEVAR治疗。